Question 1

What was Senores Pharmaceuticals' net profit in Q2 FY27?

Accepted Answer

Consolidated net profit attributable to shareholders was ₹39.5 crore, up 22.0% from ₹32.4 crore in Q2 FY26 and up 28.6% from ₹30.7 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹36.6 crore.

Question 2

How were Senores Pharmaceuticals' Q2 FY27 results?

Accepted Answer

Both grew from a year earlier: net profit was up 22.0% at ₹39.5 crore and revenue was up 18.9% at ₹192 crore. The operating margin was 24.7%, down 1.0 percentage points from 25.6% a year earlier. Against Q1 FY27, net profit was up 28.6% and revenue up 6.7%.

Question 3

What was Senores Pharmaceuticals' operating margin in Q2 FY27?

Accepted Answer

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹47.4 crore, a margin of 24.7%, against 24.3% in Q1 FY27 and 25.6% in Q2 FY26. EBITDA was ₹57.7 crore, 30.0% of revenue.

Question 4

What was Senores Pharmaceuticals' revenue in Q2 FY27?

Accepted Answer

Revenue from operations was ₹192 crore, up 18.9% year on year and up 6.7% from the previous quarter.

Question 5

What was Senores Pharmaceuticals' EPS in Q2 FY27?

Accepted Answer

Basic earnings per share were ₹8.85, against ₹6.54 in Q2 FY26.

Question 6

What was Senores Pharmaceuticals' revenue in FY26?

Accepted Answer

Revenue from operations was ₹633 crore in FY26 (April 2025–March 2026), up 58.9% from ₹398 crore in FY25.

Question 7

What was Senores Pharmaceuticals' net profit in the first half of FY27?

Accepted Answer

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹70.2 crore, up 34.7% from ₹52.1 crore in the same months a year earlier. Revenue from operations was ₹373 crore, up 24.3%.

Question 8

What is Senores Pharmaceuticals' net profit margin?

Accepted Answer

Senores Pharmaceuticals' net profit margin was 20.5% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 20.0% in Q2 FY26 (up 0.5 percentage points). For FY26 as a whole it was 19.2%.

Question 9

How has Senores Pharmaceuticals' profit changed over the last four quarters?

Accepted Answer

Net profit attributable to shareholders by quarter: ₹31.7 crore in Q3 FY26, ₹36.7 crore in Q4 FY26, ₹30.7 crore in Q1 FY27 and ₹39.5 crore in Q2 FY27. That is ₹139 crore over the four quarters, up 58.8% from ₹87.3 crore in the four quarters before. Revenue from operations: ₹175 crore, ₹175 crore, ₹180 crore and ₹192 crore.

Question 10

What was Senores Pharmaceuticals' net profit in FY26?

Accepted Answer

Consolidated net profit attributable to shareholders was ₹122 crore in FY26 (April 2025–March 2026), up 108.3% from ₹58.3 crore in FY25.

Question 11

When will Senores Pharmaceuticals announce its Q3 FY27 results?

Accepted Answer

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Question 12

Where do these Senores Pharmaceuticals figures come from?

Accepted Answer

From Senores Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed. Growth compares the same consolidated figures a year and a quarter earlier.

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	192	162	+18.9%
EBITDA	57.7	49.5	+16.5%
EBITDA margin	30.0%	30.6%	−0.6 pts
Profit before tax	47.6	40.6	+17.1%
Net profit	36.6	30.1	+21.5%
EPS	₹8.85	₹6.54	+35.3%

Expenses
	192	180	175	175	162	138	114	103
	8.9	2.8	17.7	3.8	5.4	3.4	11.8	5.2
	201	183	193	178	167	141	126	108
	28.4	31.2	27.1	37.0	46.1	29.4	20.9	23.1
	37.5	34.0	35.7	37.9	11.0	27.6	29.1	22.1
	0.7	0.6	3.5	−7.8	−0.0	4.4	7.5	−4.5
	32.4	29.9	30.3	30.7	29.6	21.7	14.6	19.0
	8.8	7.2	8.5	5.3	6.2	5.0	5.3	6.2
	10.3	9.9	9.3	7.9	8.1	6.0	5.2	4.2
	35.7	30.8	31.2	22.9	25.6	20.8	22.7	17.6
	154	144	145	134	127	115	105	87.7
	57.7	53.8	47.5	54.0	49.5	34.2	19.4	25.7
	47.4	43.8	38.2	46.2	41.4	28.2	14.2	21.5
Profit
	47.6	39.5	47.4	44.6	40.6	26.5	20.7	20.5
	47.6	39.5	47.4	44.6	40.6	26.5	20.7	20.5
	12.7	9.8	−5.0	8.6	11.4	4.9	6.7	6.1
	−1.7	−0.8	15.7	2.4	−0.8	0.4	−4.0	−2.0
	11.0	9.0	10.7	11.0	10.5	5.3	2.7	4.1
	36.6	30.5	36.7	33.6	30.1	21.2	18.0	16.4
	36.6	30.5	36.7	33.6	30.1	21.2	18.0	16.4
	3.4	0.5	41.9	−4.8	−8.4	0.5	−0.1	−2.2
	40.0	31.0	78.6	28.8	21.7	21.7	17.9	14.2
	39.5	30.7	36.7	31.7	32.4	19.7	—	17.2
	−2.9	−0.3	0.0	1.9	−2.3	1.5	—	−0.8
Per share
	₹8.85	₹6.61	₹7.96	₹7.29	₹6.54	₹4.60	₹3.81	₹5.04
	₹8.82	₹6.60	₹7.96	₹7.29	₹6.54	₹4.60	₹3.81	₹5.04
Other comprehensive income — detail
	3.4	0.5	41.9	−4.8	−8.4	0.5	−0.1	—
	0.0	—	0.2	−0.1	−0.1	—	—	0.1
	0.0	0.0	0.1	−0.0	−0.0	—	—	—
	—	—	—	—	—	—	—	0.0
	3.4	0.5	41.8	−4.7	—	—	—	−2.2
	0.0	0.0	0.0	0.0	8.3	−0.5	0.1	—
	43.3	31.2	—	28.0	25.7	20.1	—	15.3
	−3.3	−0.2	—	0.8	−4.0	1.6	—	−1.1
Per share — as-filed variants
	₹8.85	₹6.61	₹7.96	₹7.29	₹6.54	₹4.60	₹3.81	₹5.04
	₹8.82	₹6.60	₹7.96	₹7.29	₹6.54	₹4.60	₹3.81	₹5.04
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	126	114	109	108	105	76.6	56.8	62.3
	65.4%	63.5%	62.2%	61.6%	64.7%	55.5%	49.7%	60.5%
Adjusted (ex-exceptional items) — derived
	47.6	39.5	47.4	44.6	40.6	26.5	20.7	20.5
	36.6	30.5	36.7	33.6	30.1	21.2	18.0	16.4
	₹8.85	₹6.61	₹7.96	₹7.29	₹6.54	₹4.60	₹3.81	₹5.04

In ₹ Crore except Per Share 3 Months Ending	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	103.0	114.2	138.0	161.8	174.6	175.2	180.2	192.3
Other Income	5.2	11.8	3.4	5.4	3.8	17.7	2.8	8.9
Total Income	108.2	126.0	141.4	167.2	178.3	192.9	183.0	201.3
Expenses
+ Cost of Materials Consumed	23.1	20.9	29.4	46.1	37.0	27.1	31.2	28.4
+ Purchases of Stock-in-Trade	22.1	29.1	27.6	11.0	37.9	35.7	34.0	37.5
+ Changes in Inventories	-4.5	7.5	4.4	-0.0	-7.8	3.5	0.6	0.7
+ Employee Benefit Expense	19.0	14.6	21.7	29.6	30.7	30.3	29.9	32.4
+ Finance Costs	6.2	5.3	5.0	6.2	5.3	8.5	7.2	8.8
+ Depreciation & Amortisation	4.2	5.2	6.0	8.1	7.9	9.3	9.9	10.3
+ Other Expenses	17.6	22.7	20.8	25.6	22.9	31.2	30.8	35.7
Total Expenses	87.7	105.3	114.9	126.5	133.7	145.5	143.6	153.7
EBITDA	25.7	19.4	34.2	49.5	54.0	47.5	53.8	57.7
EBIT	21.5	14.2	28.2	41.4	46.2	38.2	43.8	47.4
Profit
PBT before Exceptional Items	20.5	20.7	26.5	40.6	44.6	47.4	39.5	47.6
Pretax Income	20.5	20.7	26.5	40.6	44.6	47.4	39.5	47.6
+ Current Tax	6.1	6.7	4.9	11.4	8.6	-5.0	9.8	12.7
+ Deferred Tax	-2.0	-4.0	0.4	-0.8	2.4	15.7	-0.8	-1.7
Tax Expense	4.1	2.7	5.3	10.5	11.0	10.7	9.0	11.0
Net Income	16.4	18.0	21.2	30.1	33.6	36.7	30.5	36.6
+ Net Income — Continuing Ops	16.4	18.0	21.2	30.1	33.6	36.7	30.5	36.6
+ Other Comprehensive Income	-2.2	-0.1	0.5	-8.4	-4.8	41.9	0.5	3.4
Total Comprehensive Income	14.2	17.9	21.7	21.7	28.8	78.6	31.0	40.0
Net Income to Common	17.2	—	19.7	32.4	31.7	36.7	30.7	39.5
Minority Interest	-0.8	—	1.5	-2.3	1.9	0.0	-0.3	-2.9
Per Share
Basic EPS	5.04	3.81	4.60	6.54	7.29	7.96	6.61	8.85
Diluted EPS	5.04	3.81	4.60	6.54	7.29	7.96	6.60	8.82
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	-0.1	0.5	-8.4	-4.8	41.9	0.5	3.4
+ Items NOT to be Reclassified to P&L	0.1	—	—	-0.1	-0.1	0.2	—	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	-0.0	-0.0	0.1	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-2.2	—	—	—	-4.7	41.8	0.5	3.4
+ Tax on Items to be Reclassified	—	0.1	-0.5	8.3	0.0	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	15.3	—	20.1	25.7	28.0	—	31.2	43.3
Comprehensive Income — Non-controlling Interests	-1.1	—	1.6	-4.0	0.8	—	-0.2	-3.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	5.04	3.81	4.60	6.54	7.29	7.96	6.61	8.85
Diluted EPS — Continuing Operations	5.04	3.81	4.60	6.54	7.29	7.96	6.60	8.82
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	62.3	56.8	76.6	104.7	107.5	109.0	114.5	125.8
Gross Margin %	60.49	49.69	55.53	64.71	61.61	62.20	63.53	65.38
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	20.5	20.7	26.5	40.6	44.6	47.4	39.5	47.6
Net Income Adj (tax-effected)	16.4	18.0	21.2	30.1	33.6	36.7	30.5	36.6
EPS Adj	5.04	3.81	4.60	6.54	7.29	7.96	6.61	8.85
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	46.1	46.1	46.1	46.1	46.1	46.1	46.1	46.1

Senores Pharmaceuticals quarterly results

Every quarter

Senores Pharmaceuticals Limited

Senores Pharmaceuticals Q2 FY27 results (July–September 2026)

Q2 FY27 at a glance · consolidated

Questions